NC cancer survivor set for collegiate football career - WCNC
NC cancer survivor set for collegiate football career WCNC
Hodgkin Lymphoma News
Worse HIV control at diagnosis doesn't mean worse lymphoma outcomes - Aidsmap
Worse HIV control at diagnosis doesn't mean worse lymphoma outcomes Aidsmap
Brown-Shuler to Undergo Treatment for Hodgkin Lymphoma - Clemson University Athletics
Brown-Shuler to Undergo Treatment for Hodgkin Lymphoma Clemson University Athletics
UNC Study Reveals Promising New Therapy for Non-Hodgkin Lymphoma - UNC Health
UNC Study Reveals Promising New Therapy for Non-Hodgkin Lymphoma UNC Health
FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma - Targeted Oncology
FDA Orphan Drug Status Awarded to EO2463 in Indolent Non-Hodgkin Lymphoma Targeted Oncology
Legend surges on early data for ‘in vivo’ lymphoma cell therapy - BioPharma Dive
Legend surges on early data for ‘in vivo’ lymphoma cell therapy BioPharma Dive
Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 - Fortune Business Insights
Non-Hodgkin Lymphoma Treatment Market Size, Forecast, 2034 Fortune Business Insights
Understanding the Origins of Hodgkin Lymphoma Cells Could Lead to Better Diagnostics - WCM Newsroom
Understanding the Origins of Hodgkin Lymphoma Cells Could Lead to Better Diagnostics WCM Newsroom
AZD3470 at ASCO 2026: a promising new drug for Hodgkin lymphoma? - Clinical Trials Arena
AZD3470 at ASCO 2026: a promising new drug for Hodgkin lymphoma? Clinical Trials Arena
Clemson football player Hevin Brown-Schuler gives an update on his Hodgkin lymphoma battle - FOX Carolina News
Clemson football player Hevin Brown-Schuler gives an update on his Hodgkin lymphoma battle FOX Carolina News
Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response | Blood Cancer Journal - Nature
Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response | Blood Cancer Journal Nature
Palmetto Sports’ Ella Grogan updates Clemson DT Hevin Brown-Shuler’s Hodgkin Lymphoma diagnosis. - WIS News 10
Palmetto Sports’ Ella Grogan updates Clemson DT Hevin Brown-Shuler’s Hodgkin Lymphoma diagnosis. WIS News 10
Teen who began chemo before high school now graduating with perfect GPA, $125K scholarship - Fox News
Teen who began chemo before high school now graduating with perfect GPA, $125K scholarship Fox News
Clemson DT to miss 2026 season while undergoing treatment for Hodgkin lymphoma - The Athletic - The New York Times
Clemson DT to miss 2026 season while undergoing treatment for Hodgkin lymphoma - The Athletic The New York Times
Legend soars on ‘best-in-class,’ ‘best-in-disease’ in vivo CAR T in early lymphoma study - BioSpace
Legend soars on ‘best-in-class,’ ‘best-in-disease’ in vivo CAR T in early lymphoma study BioSpace
How Clemson football's Hevin Brown-Shuler discovered he had Hodgkin lymphoma - Greenville Online
How Clemson football's Hevin Brown-Shuler discovered he had Hodgkin lymphoma Greenville Online
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) - Yahoo Finance
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) Yahoo Finance
Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma - CancerNetwork
Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma CancerNetwork
Arkansas softball pitcher with Hodgkin's Lymphoma surprised with trip to Women's College World Series - thv11.com
Arkansas softball pitcher with Hodgkin's Lymphoma surprised with trip to Women's College World Series thv11.com
FDA Approves Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma - OncLive
FDA Approves Nivolumab Plus AVD for Untreated Classical Hodgkin Lymphoma OncLive
Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin Lymphoma in the United States: a population-based cohort study - Nature
Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin Lymphoma in the United States: a population-based cohort study Nature
Nivolumab/AVD: A New Standard in Untreated Advanced Hodgkin Lymphoma - CancerNetwork
Nivolumab/AVD: A New Standard in Untreated Advanced Hodgkin Lymphoma CancerNetwork
'Incredible' Hodgkin Lymphoma Clinical Trial Study - Mirage News
'Incredible' Hodgkin Lymphoma Clinical Trial Study Mirage News
Health Canada authorizes Lunsumio® (mosunetuzumab) for the treatment of relapsed or refractory follicular lymphoma after two or more systemic therapies - Cantech Letter
Health Canada authorizes Lunsumio® (mosunetuzumab) for the treatment of relapsed or refractory follicular lymphoma after two or more systemic therapies Cantech Letter
Novel combination therapy yields high response rates in early-stage classical Hodgkin lymphoma - UT MD Anderson
Novel combination therapy yields high response rates in early-stage classical Hodgkin lymphoma UT MD Anderson
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates - Iowa Capital Dispatch
Report: Counties that spray the most glyphosate have higher non-Hodgkin lymphoma rates Iowa Capital Dispatch
Consecutive approvals of Opdivo for Hodgkin’s lymphoma to boost sales growth - Clinical Trials Arena
Consecutive approvals of Opdivo for Hodgkin’s lymphoma to boost sales growth Clinical Trials Arena
Early lymphoma trial: one-time CAR-T saw all higher-dose patients respond - Stock Titan
Early lymphoma trial: one-time CAR-T saw all higher-dose patients respond Stock Titan
FDA Approves Nivolumab/AVD in Untreated Hodgkin Lymphoma - CancerNetwork
FDA Approves Nivolumab/AVD in Untreated Hodgkin Lymphoma CancerNetwork
Clemson football player stepping away for treatment after cancer diagnosis - The State
Clemson football player stepping away for treatment after cancer diagnosis The State
FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma - The ASCO Post
FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma The ASCO Post
Hodgkin Lymphoma (HL): Microenvironmental Biology Behind a Therapeutic Success Story - Oncodaily
Hodgkin Lymphoma (HL): Microenvironmental Biology Behind a Therapeutic Success Story Oncodaily
Nivolumab Wins Multiple FDA Approvals for Classical Hodgkin Lymphoma - Pharmacy Times
Nivolumab Wins Multiple FDA Approvals for Classical Hodgkin Lymphoma Pharmacy Times
New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy - UT MD Anderson
New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy UT MD Anderson
Nodular lymphocyte-predominant Hodgkin lymphoma: Leah's story - Roswell Park Comprehensive Cancer Center
Nodular lymphocyte-predominant Hodgkin lymphoma: Leah's story Roswell Park Comprehensive Cancer Center
Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report - Frontiers
Primary extranodal marginal zone non-hodgkin lymphoma of the prostate: a case report Frontiers
Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma - CancerNetwork
Rethinking Dual Targeting, Durability After CAR-T in Non-Hodgkin Lymphoma CancerNetwork
Young mother’s Hodgkin lymphoma diagnosis felt ‘devastating’ - Fred Hutchinson Cancer Center
Young mother’s Hodgkin lymphoma diagnosis felt ‘devastating’ Fred Hutchinson Cancer Center
Nivolumab Outperforms Brentuximab Vedotin in PFS in Classic Hodgkin Lymphoma - Targeted Oncology
Nivolumab Outperforms Brentuximab Vedotin in PFS in Classic Hodgkin Lymphoma Targeted Oncology
‘The Sister Act’: How family and faith helped a young woman beat Hodgkin’s lymphoma - University of California - Davis Health
‘The Sister Act’: How family and faith helped a young woman beat Hodgkin’s lymphoma University of California - Davis Health